-
Most Recent
Search Results
240 results for CTX
The Biggest Winner From Nvidia’s RTX Spark Announcement Isn’t Nvidia
Nvidia’s RTX Spark just entered the PC market. The obvious trade is NVDA — but the cleanest win may already be collecting royalties.
Why This Market Is Like a Sports Car – and How You Should Drive It
In today’s Market 360, I’ll show you why this market is no place for white-knuckle guessing – and why my InvestorPlace colleague Jonathan Rose may…
The AI Job Shake-Up Could Create Big Winners – and Losers
There is a new type of AI making its debut that doesn’t answer questions and or wait for instructions. It goes out into the world,…
The Backlash to “Train Your Replacement” Begins
The cold math behind Oracle’s mass layoffs… the Prisoner’s Dilemma, live and in person… Luke Lango describes the backlash that could end the AI bull…
$725 Billion and Counting: Why the AI Gusher Is Just Getting Started
The Mag 7 committed $725B to AI capex with no peak in sight. Here are the downstream AI stocks positioned to catch the windfall.
Builder Pulte Breaking Out
New buy signals could be telling us that PHM could breakout from a long-term base.
CRSP Stock: The Good News Goosing CRISPR Therapeutics Shares Today
Shares of CRSP stock are rising on Friday after CRISPR Therapeutics provided a positive business update regarding its leading drug candidate.
CRISPR Therapeutics Rallies as Gene Stocks Get Hot Again
CRSP is testing its gene editing therapies in sicke cell disease and cancer. These therapies could eventually boost CRSP stock.
CRISPR Therapeutics Stock Looks Like a Long-Term Biotech Winner
Gene editing has the potential to revolutionize medicine. With CRISPR Therapeutics leading the way, CRSP stock should benefit.
The Next Big Thing After AI? 3 Sleeper Stocks to Buy Before the Boom
These three sleeper stocks could deliver massive gains if their cutting-edge technologies take off in the coming years.
Crispr Therapeutics News: CRSP Stock Slides 12% on Trial Death
Crispr Therapeutics (CRSP) news for Wednesday includes a patient’s death during a recent drug trial dropping CRSP stock down.
Updated Clinical and Financial Data Make the Case for CRISPR Therapeutics
Looking for a terrific value in the biotechnology space? It doesn’t get much better than CRSP stock, which just entered a buy zone.
Why Is Cingulate (CING) Stock Up 72% Today?
Cingulate (CING) stock is on the rise Friday after releasing positive data concerning its ADHD treatment, which is in a Phase 3 trial.
CRISPR Therapeutics Is One of Today’s Best Biotech Value Investments
Don’t let the downtrend in CRSP stock fool you; the company is still making headway in advancing potentially life-changing therapeutics.
The “Hypergrowth” That’s Just Beginning for This Red-Hot Medical Trend
We talk a lot here about getting into unstoppable and explosive trends early, while stock prices are still cheap and consumer sentiment is just beginning…
Rags to Riches: 3 Gene Editing Stocks That Could Make Early Investors Rich
Gene editing is a game-changer, creating substantial opportunities for some of the leading gene editing stocks.
Consider Adding New Positions in U.S. Cannabis Stocks
It’s no secret Matt McCall is searching for emerging trends. This week, he discusses cannabis stocks and a breakthrough biotech therapy.
1 – 10 of 240 results
